title: Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.
abstract: Hepatitis C virus (HCV) has emerged as a major viral pandemic over the past two decades, infecting 170 million individuals, which equates to approximately 3% of the world's population. The prevalence of HCV varies according to geographic region, being highest in developing countries such as Egypt. HCV has a high tendency to induce chronic progressive liver damage in the form of hepatic fibrosis, cirrhosis, or liver cancer. To date, there is no vaccine against HCV infection. Combination therapy comprising PEGylated interferon-alpha and ribavirin has been the standard of care for patients with chronic hepatitis C for more than a decade. However, many patients still do not respond to therapy or develop adverse events. Recently, direct antiviral agents such as protease inhibitors, polymerase inhibitors, or NS5A inhibitors have been used to augment PEGylated interferon and ribavirin, resulting in better efficacy, better tolerance, and a shorter treatment duration. However, most clinical trials have focused on assessing the efficacy and safety of direct antiviral agents in patients with genotype 1, and the response of other HCV genotypes has not been elucidated. Moreover, the prohibitive costs of such triple therapies will limit their use in patients in developing countries where most of the HCV infection exists. Understanding the host and viral factors associated with viral clearance is necessary for individualizing therapy to maximize sustained virologic response rates, prevent progression to liver disease, and increase the overall benefits of therapy with respect to its costs. Genome wide studies have shown significant associations between a set of polymorphisms in the region of the interleukin-28B (IL28B) gene and natural clearance of HCV infection or after PEGylated interferon-alpha and ribavirin treatment with and without direct antiviral agents. This paper synthesizes the recent advances in the pharmacogenetics of HCV infection in the era of triple therapies.
authors.affiliation: Department of Medicine, Division of Hepatology, Gastroenterology and Tropical Medicine, Ain Shams Faculty of Medicine, Cairo, Egypt ; Department of Medicine, Salman Bin Abdul Aziz College of Medicine, Kingdom of Saudi Arabia.
authors.forename: Sanaa M
authors.initials: SM
authors.lastname: Kamal
keywords: PEGylated interferon and ribavirin; direct-acting antiviral agents; hepatitis C virus; interleukin-28B polymorphisms; pharmacogenetics; rational therapeutics
references.citation: Nature. 2009 Sep 17;461(7262):399-401
references.pmid: 19684573
references.citation: AIDS. 2007 May 11;21(8):983-91
references.pmid: 17457092
references.citation: PLoS One. 2010 Oct 29;5(10):e13771
references.pmid: 21048934
references.citation: Annu Rev Microbiol. 2001;55:255-81
references.pmid: 11544356
references.citation: N Engl J Med. 2007 Jul 12;357(2):124-34
references.pmid: 17625124
references.citation: J Hepatol. 2011 May;54(5):866-71
references.pmid: 21145807
references.citation: Aliment Pharmacol Ther. 2004 Oct 15;20(8):825-30
references.pmid: 15479353
references.citation: Nature. 2005 Aug 18;436(7053):967-72
references.pmid: 16107837
references.citation: Gastroenterology. 2010 Sep;139(3):821-7, 827.e1
references.pmid: 20621700
references.citation: J Viral Hepat. 2007 Feb;14(2):116-21
references.pmid: 17244251
references.citation: Gastroenterology. 2010 Aug;139(2):499-509
references.pmid: 20434452
references.citation: Clin Infect Dis. 2010 Nov 15;51(10):1209-16
references.pmid: 20964522
references.citation: N Engl J Med. 2005 Jun 23;352(25):2609-17
references.pmid: 15972867
references.citation: J Clin Microbiol. 2011 May;49(5):1853-60
references.pmid: 21389156
references.citation: Gastroenterology. 2008 Aug;135(2):451-8
references.pmid: 18503773
references.citation: Clin Liver Dis. 2006 Nov;10(4):901-17
references.pmid: 17164124
references.citation: Gastroenterology. 2006 Mar;130(3):632-8
references.pmid: 16530503
references.citation: Science. 2004 Aug 6;305(5685):872-4
references.pmid: 15297676
references.citation: Med Clin North Am. 2014 Jan;98(1):17-38
references.pmid: 24266912
references.citation: Gastroenterology. 2014 Mar;146(3):736-743.e1
references.pmid: 24262278
references.citation: Biopolymers. 2000;55(4):254-87
references.pmid: 11169919
references.citation: Hepatology. 2004 Jun;39(6):1721-31
references.pmid: 15185314
references.citation: Gastroenterology. 2013 Oct;145(4):790-800.e3
references.pmid: 23811112
references.citation: Lancet. 2013 Jun 15;381(9883):2100-7
references.pmid: 23499440
references.citation: Nat Genet. 2009 Oct;41(10):1100-4
references.pmid: 19749758
references.citation: Eur J Immunol. 2000 Sep;30(9):2479-87
references.pmid: 11009080
references.citation: J Hepatol. 2006 Jan;44(1):97-103
references.pmid: 16290907
references.citation: Hepatology. 2011 Jan;53(1):336-45
references.pmid: 21254181
references.citation: Gut. 2006 Aug;55(8):1183-7
references.pmid: 16434426
references.citation: Hepatology. 2006 May;43(5):954-60
references.pmid: 16628671
references.citation: J Hepatol. 2011 Mar;54(3):415-21
references.pmid: 21112657
references.citation: J Hepatol. 2011 Aug;55(2):322-7
references.pmid: 21147186
references.citation: J Hepatol. 2011 Mar;54(3):408-14
references.pmid: 21112660
references.citation: Liver Int. 2010 Oct;30(9):1259-69
references.pmid: 20633102
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S21-9
references.pmid: 12407573
references.citation: Gut. 2011 Feb;60(2):261-7
references.pmid: 21068134
references.citation: J Viral Hepat. 2010 May;17(5):345-51
references.pmid: 19780947
references.citation: J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):31-6
references.pmid: 16340470
references.citation: Liver. 2000 Jul;20(4):281-9
references.pmid: 10959806
references.citation: Hepatology. 2007 Dec;46(6):1732-40
references.pmid: 17943989
references.citation: J Hepatol. 2012 Mar;56(3):527-32
references.pmid: 21951981
references.citation: J Virol. 2004 Nov;78(22):12252-8
references.pmid: 15507612
references.citation: Hepatology. 2011 Jan;53(1):14-22
references.pmid: 21254158
references.citation: Annu Rev Microbiol. 2004;58:391-424
references.pmid: 15487943
references.citation: AIDS. 2010 May 15;24(8):F23-9
references.pmid: 20389235
references.citation: Clin Liver Dis. 1997 Nov;1(3):587-602
references.pmid: 15560060
references.citation: Hepatology. 2006 Apr;43(4):771-9
references.pmid: 16557547
references.citation: N Engl J Med. 2013 May 16;368(20):1878-87
references.pmid: 23607594
references.citation: Liver Int. 2015 Jan;35(1):108-19
references.pmid: 24517252
references.citation: Antivir Ther. 2012;17(6 Pt B):1163-70
references.pmid: 23186615
references.citation: Clin Infect Dis. 2009 Jan 15;48(2):186-93
references.pmid: 19086908
references.citation: J Antimicrob Chemother. 2006 Feb;57(2):360-3
references.pmid: 16396921
references.citation: J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):95-9
references.pmid: 21157362
references.citation: J Viral Hepat. 2011 Apr;18(4):e66-74
references.pmid: 21070502
references.citation: AIDS. 2013 Jul 31;27(12):1941-7
references.pmid: 23917425
references.citation: J Interferon Cytokine Res. 2010 Aug;30(8):555-64
references.pmid: 20712453
references.citation: Gastroenterology. 1997 Mar;112(3):1017-21
references.pmid: 9041265
references.citation: AIDS. 2011 Mar 27;25(6):761-6
references.pmid: 21378537
references.citation: PLoS One. 2011 Feb 24;6(2):e17232
references.pmid: 21390311
references.citation: J Viral Hepat. 2009 Sep;16(9):650-8
references.pmid: 19413698
references.citation: Gastroenterology. 2010 Nov;139(5):1586-92, 1592.e1
references.pmid: 20637200
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: Clin Drug Investig. 2013 May;33(5):325-31
references.pmid: 23532802
references.citation: J Viral Hepat. 2006 Jan;13(1):34-41
references.pmid: 16364080
references.citation: Gastroenterology. 2010 Nov;139(5):1577-85, 1585.e1-3
references.pmid: 20708617
references.citation: Hepatology. 2002 May;35(5):1002-9
references.pmid: 11981750
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S173-8
references.pmid: 12407591
references.citation: Nature. 2009 Oct 8;461(7265):798-801
references.pmid: 19759533
references.citation: J Infect Dis. 2008 Oct 15;198(8):1159-65
references.pmid: 18781864
references.citation: J Infect Dis. 2011 Mar 1;203(5):595-601
references.pmid: 21257738
references.citation: Springerplus. 2013 Jun 01;2(1):251
references.pmid: 23772356
references.citation: J Hepatol. 2011 Mar;54(3):439-48
references.pmid: 21129805
references.citation: J Hepatol. 1997 Feb;26(2):236-43
references.pmid: 9059941
references.citation: Hepatology. 2013 Dec;58(6):1918-29
references.pmid: 23907700
references.citation: Lancet. 2014 Feb 8;383(9916):515-23
references.pmid: 24209977
references.citation: Hepatology. 2006 May;43(5):923-31
references.pmid: 16628640
references.citation: Clin Infect Dis. 2010 Oct 1;51(7):788-95
references.pmid: 20804372
references.citation: Virology. 2013 Sep;444(1-2):292-300
references.pmid: 23866096
references.citation: Hepatology. 2006 Feb;43(2):250-6
references.pmid: 16440367
references.citation: Liver Int. 2011 Mar;31(3):401-11
references.pmid: 21281434
references.citation: J Exp Med. 2001 Nov 19;194(10):1395-406
references.pmid: 11714747
references.citation: Ann Intern Med. 2006 May 16;144(10):705-14
references.pmid: 16702586
references.citation: Liver Int. 2009 Jan;29 Suppl 1:74-81
references.pmid: 19207969
references.citation: Gastroenterology. 2010 Jul;139(1):120-9.e18
references.pmid: 20399780
references.citation: Clin Infect Dis. 2007 Sep 1;45(5):583-8
references.pmid: 17682992
references.citation: J Infect Dis. 2011 Jul 1;204(1):84-93
references.pmid: 21628662
references.citation: Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3081-6
references.pmid: 11880647
references.citation: Gastroenterology. 2010 Apr;138(4):1338-45, 1345.e1-7
references.pmid: 20060832
references.citation: Hepatology. 2010 Dec;52(6):1888-96
references.pmid: 20931559
references.citation: J Med Virol. 2012 Jul;84(7):1106-14
references.pmid: 22585729
references.citation: Aliment Pharmacol Ther. 2014 Jan;39(1):104-11
references.pmid: 24205831
references.citation: J Exp Med. 2000 May 1;191(9):1499-512
references.pmid: 10790425
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Gastroenterology. 2001 Sep;121(3):646-56
references.pmid: 11522749
references.citation: Gastroenterology. 2010 Jun;138(7):2307-14
references.pmid: 20176026
references.citation: J Hepatol. 2013 Aug;59(2):205-12
references.pmid: 23542346
references.citation: Am J Gastroenterol. 2014 Feb;109(2):199-211
references.pmid: 24445571
references.citation: Hepatology. 2011 Nov;54(5):1518-26
references.pmid: 22006276
references.citation: Hepatology. 2010 Oct;52(4):1216-24
references.pmid: 20803561
references.citation: J Med Virol. 2012 Jul;84(7):1097-105
references.pmid: 22585728
references.citation: Nat Genet. 2009 Oct;41(10):1105-9
references.pmid: 19749757
references.citation: Liver Int. 2014 Feb;34 Suppl 1:60-8
references.pmid: 24373080
references.citation: Clin Infect Dis. 2006 Nov 1;43(9):1154-9
references.pmid: 17029134
references.citation: Hepatology. 2010 Jul;52(1):33-7
references.pmid: 20578254
references.citation: Clin Microbiol Rev. 2007 Jan;20(1):23-38
references.pmid: 17223621
references.citation: Euro Surveill. 2003 May;8(5):99-100
references.pmid: 12799475